Shelton Capital Management Purchases 7,100 Shares of Humana Inc. (NYSE:HUM)

Shelton Capital Management boosted its position in Humana Inc. (NYSE:HUM - Free Report) by 148.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,892 shares of the insurance provider's stock after buying an additional 7,100 shares during the quarter. Shelton Capital Management's holdings in Humana were worth $3,017,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. FPC Investment Advisory Inc. bought a new stake in shares of Humana during the 4th quarter worth approximately $27,000. Centricity Wealth Management LLC bought a new stake in Humana during the fourth quarter worth $30,000. LFA Lugano Financial Advisors SA lifted its stake in Humana by 56.3% in the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock valued at $32,000 after acquiring an additional 45 shares during the last quarter. OFI Invest Asset Management bought a new position in shares of Humana in the 4th quarter valued at about $33,000. Finally, Atwood & Palmer Inc. increased its stake in shares of Humana by 64.5% during the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider's stock worth $39,000 after purchasing an additional 60 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on HUM shares. Barclays raised their target price on shares of Humana from $270.00 to $322.00 and gave the company an "equal weight" rating in a research note on Friday. Guggenheim started coverage on Humana in a research note on Wednesday, April 9th. They set a "buy" rating and a $326.00 target price for the company. StockNews.com upgraded Humana from a "hold" rating to a "buy" rating in a research note on Monday, April 7th. Mizuho raised their price target on Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a report on Wednesday, April 9th. Finally, Cantor Fitzgerald reiterated a "neutral" rating and issued a $290.00 price objective on shares of Humana in a report on Wednesday, February 12th. Seventeen equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $288.60.

Remove Ads

Humana Price Performance

Shares of Humana stock traded down $8.88 during trading on Monday, reaching $286.16. 415,895 shares of the company's stock were exchanged, compared to its average volume of 1,747,085. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $406.46. The company has a market cap of $34.54 billion, a P/E ratio of 28.76, a PEG ratio of 2.05 and a beta of 0.62. The firm's 50-day moving average price is $265.55 and its 200 day moving average price is $270.35.

Humana (NYSE:HUM - Get Free Report) last released its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, research analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a $0.885 dividend. The ex-dividend date is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a yield of 1.24%. Humana's dividend payout ratio is currently 35.58%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.